Malcolm Sperling, M.D.

Dr. Sperling is the Director of Edinger Medical Group's Clinical Research Center. Dr. Sperling completed both college and medical school at the University of Illinois. He completed his surgical residency at the West side VA Hospital in Chicago and is certified by the American Board of Surgery. He is the former Chairman of the Department of Surgery, as well as the Credentials and Utilization Review Committee at Fountain Valley Regional Hospital.

Back To Top

About the Research Center

Edinger Medical Group Research Center opened in 1989 facilitating patient participation in the clinical studies of major pharmaceutical companies. The Research department was well received by Edinger patients and by the community. Since its inception, over 200 clinical trials have been conducted at Edinger Medical Group and the data obtained through these studies have assisted in the FDA approval of many medications prescribed by physicians globally.

Edinger Focuses on Cutting Edge Research

Edinger Medical Group & Research Center continues to provide state-of-the-art research opportunities offering our patients medications and vaccines sometimes years prior to them becoming available to the general public. We intend to focus on vaccines and biopharmaceutical research - the cutting edge of medicine of the future.

Most recently, our Research Center has participated in some important vaccine studies that have played significant roles in health care prevention today.

• Protection against meningococcus (a bacteria that causes life threatening infections) with a newer, better conjugate vaccine (Menactra) was given to many of our patients up to three years before FDA approval. This vaccine is now either required or strongly encouraged by all colleges and universities for incoming students.
• Human Papilloma Virus or HPV infections are acquired by most women at some time. A frequent cause of abnormal Pap smears, most infections spontaneously disappear over months or years. Some go on to cause cervical cancer. An HPV vaccine against the serotypes responsible for about 75% of cervical cancers is now FDA approved and recommended for females age 11-18. This safe, effective vaccine was offered through our Research Center to many of our teen patients up to three years prior to FDA approval.
• Shingles (herpes zoster) is a painful rash caused by reactivation of the chicken pox virus. The shingles nerve pain can be severe and, in some cases, persistently painful. In 2005, some of our senior patients participated in a vaccine study to prevent this disease. The vaccine is now FDA approved.
• A live-attenuated (weakened) influenza nose spray vaccine has been FDA approved for healthy 5-49 year olds for three years. It appears that this vaccine is far more protective against influenza viral infections than the injected vaccine in younger children. We were involved in the pivotal study to approve the live-attenuated nasal spray influenza vaccine for children ages 1-5. The study has been completed and the data confirming safety and better efficacy has been submitted to the FDA. It is anticipated that the FDA will approve the vaccine for children down to age one year for the 2007-2008 influenza season.

We carefully screen all research studies and only approve the ones we feel are very likely to be safe and beneficial to our patients. Ask your physician for more information on our upcoming studies or call our Research Center at (714) 965 2526.

Insurance is not required to participate in the trials and there is no cost to patients. Qualified participants may receive study-related physical exams, laboratory tests, study medication, and reimbursement for time and travel. Our studies frequently change, please call for updates or send us a message..

Back To Top